Twenty-nine intact, working pig hearts were extracorporeally perfused and divided into two study groups (16 Aerobic and 13 Ischemic/Reflow hearts).
minutes to come into equilibrium.1101' Thus, the purpose of the present studies was 1) to review further the substrate kinetics of long-chain fatty acids leading to CO2 production, with particular attention paid to the time constants of incorporation and distribution of substrate; and 2) to contrast the metabolic behavior between aerobically perfused hearts and those rendered ischemic and then reperfused.
Materials and Methods
Twenty-nine adolescent swine weighing 48.9±0.6 kg were studied. Sixteen of these animals also had been used in a separate study (unpublished data) to develop baseline characteristics of fatty acid utilization kinetics but in this study served as a control (Aerobic) group to contrast with observations acquired in a separate group (Ischemic/Reflow) during reperfusion after ischemia. Data for both studies were obtained contemporaneously. All animals were anesthetized with pentobarbital (35 mg/kg i.v.) and underwent establishment of controlled positive pressure ventilation using oxygen-supplemented room air. The preparation used in this study has been reported extensively elsewhere.10'12'3 Briefly, the coronary arteries were perfused separately via an arterioarterial shunt connected extracorporeally. Blood was withdrawn from a femoral artery and returned by three low flow perfusion pumps to proximally cannulated right, main left, and left anterior descending (LAD) coronary arteries. Three access ports were included in the LAD perfusion circuit. One port allowed infusion of indocyanine green directly into the perfusion circuit through a 50 -ml mixing chamber. Another port was for infusion of [14C]palmitate (48±3 ,uCi/animal), which was mixed with the perfusate by passage of the isotope through a segment of tubing (8-ml volume) contained in series within the perfusion circuit consisting of alternating sections of small-bore (0.64-cm i.d.) and large-bore (1.3-cm i.d.) tubing. A third port was used to sample arterial blood for gases and metabolites; this blood was compared with venous blood obtained from a sampling catheter inserted anteriorly into the great cardiac vein.
Left ventricular pressure and its maximal first derivative were measured by a high-fidelity, manometer-tipped pressure device (Millar Instruments, Houston, Tex.) placed into the left ventricular chamber. Regional function was estimated from myocardial shortening as measured by ultrasonic crystals placed at midmyocardial depth in the LAD perfusion system. Segment shortening was used to characterize regional contractility.
Aerobic coronary flows were adjusted so that coronary perfusion pressures approximated arterial pressures, and the venous oxygen saturations were estimated at or about 40%.
By prospectively agreed-on entrance criteria, venous saturations in Aerobic hearts were not permitted to decrease below 20% at any time in the perfusion trial. To set conditions of near constant myocardial oxygen demand in all hearts, blood volumes were replaced with 6% dextran in saline to maintain systemic pressures at approximately 100 mm Hg. Serum glucose levels were monitored continuously and maintained at 7.1+0.04 gtmol/ml with intravenous infusions of dextrose. Indocyanine green indicator (0.33 mg/ml) was infused into the LAD perfusate for 5 minutes every 10 minutes at a flow rate of 1.0 ml/min during the radiolabeled perfusion period to measure the cross-contamination of any unlabeled coronary blood entering the venous system of the LAD circuit. From this, a dilution factor was calculated to correct the venous counts that then were used in the calculations.
Metabolic and mechanical data were obtained at specified intervals throughout the perfusion studies. Blood samples obtained from the LAD artery and vein were used to measure blood gases and 1'4CO2 production from labeled palmitate. The former samples were used to calculate regional myocardial oxygen consumption (MVo2 in millimoles per hour per gram dry weight) by a previously described formula. 12 The latter samples were centrifuged at 1,500g at 4°C for 10 minutes to obtain plasma. Blood from the femoral artery likewise was centrifuged to acquire a similar plasma fraction. These plasma samples from the LAD artery, great cardiac vein, and femoral artery were counted to measure total radiocarbon in the blood. 1 Coronary arterial blood samples for 14CO2 measurements were obtained every 5 minutes throughout the studies, and coronary arterial samples together with femoral arterial samples were collected every 10 minutes to analyze for non-14C02 radioactivity. For the Aerobic hearts, venous blood samples for CO2 data were obtained every 2 minutes throughout the 40-minute labeling period, and venous plasma samples were collected every 0.5 minute for 3 minutes, then every 2 minutes for the rest of the 40-minute labeling period. Arterial CO2 and plasma samples together with femoral arterial samples were taken every 10 minutes for 40 minutes. During the washout period, blood was obtained at the same time intervals as described above for the Ischemic/Reflow group.
Statistical comparisons of data were made within each group using paired Student's t tests and between groups using nonpaired Student's t tests. Statistical significance was defined by two-tailed probability values less than 5%.
Results Figure 2 shows coronary flows and left ventricular pressures for both Ischemic/Reflow and Aerobic groups. Venous oxygen saturations in the LAD bed at aerobic perfusions (0-10 minutes) were comparable between groups, although flow rates were slightly higher in Aerobic hearts (7.1+0.3 versus 6.0+0.3 ml/min/g dry wt, p<0.034). We do not feel this difference is physiologically significant. The LAD flow in Aerobic hearts was purposely maintained slightly higher than that required to meet the metabolic demands of the heart. This perfusion level was selected to guarantee that the tissue would not be exposed to ischemic conditions. In the Ischemic/ Reflow group, LAD flow was reduced to 2.4±0.1 ml/min/g dry wt during ischemia and then acutely returned to preischemic levels at 40 minutes. Circumflex plus right coronary flows in Aerobic and Ischemic/Reflow hearts were maintained at 11.3 ±0.6 and 10.2±0.6 ml/min/g dry wt, respectively, throughout the experiments. Left ventricular pressure averaged 102.5± 1.2 mm Hg for both groups throughout the perfusion trial and was not statistically different between groups. Serum fatty acids were 0.51±0.04
,umol/ml, and blood sugar concentrations were 7.13±0.04 ,umol/ml (average of all animals in both groups). Neither substrate level was statistically different between groups. Figure 3 shows regional mechanical and metabolic performance in the two groups. Aerobic values for both systolic shortening and myocardial oxygen consumption were steady over the course of the perfusion trials (not significant in the middle [10- [14C]Palmitate was added to blood that had no radioactive material present. The amount of radioactivity added was such that the counts were similar to those of blood taken from the in vivo studies (approximately 6 x 104 dpm/ml). The distribution of radioactivity in this in vitro labeled blood then was determined in a manner identical to the approach used with the in vivo samples. These spiked standard data represent the distribution of "normal" contamination of radioactivity affected by adding fatty acids to blood constituents independent of products accumulating from myocardial metabolism. These data are compared with the Ischemic/Reflow blood ( Table 1) . Distribution of radioactivity in coronary venous effluent was almost totally contained in the organic or fatty acid compartments, with a small additional component noted in the aqueous soluble phase and phospholipids. The distribution was nearly identical to the pattern in the nonmetabolized spiked standard data. Indeed, the only significant metabolized product to be released from labeled fatty acid utilization in hearts was 14C02.
Uptake and washout of fatty acids and 14CO2 are shown for two representative animals in the Ischemic/Reflow group in Figures 4 and 5 and for both groups in Table 2 . Again, in the uptake studies, there Constant=57.1-0.25 x heart rate; r=0.62, p<0.0004 (all animals included from both groups). In separate studies in 10 animals, washout curve analysis also was performed ( Figure 5 , Table 2 ). Exponential decay of counts was similar between groups but different between labeled constituents. (Table 3) . In uptake studies in Aerobic hearts, counts between lipid and aqueous soluble phases were almost evenly divided (52% and 48%, respectively), whereas in Ischemic/ Reflow hearts, counts were increased in the lipid fraction (66%). Generally, there were no major statistical differences between groups among the various fractions and lipid species in either the uptake or washout data. Triacylglycerol radioactivity tended to be higher in the Ischemic/Reflow group, and the aqueous soluble phase radioactivity was slightly smaller as measured by the volume equivalency method. In washout studies, counts in complex lipids and cholesterol/cholesteryl esters in both groups remained relatively fixed, with more variability noted in the triacylglycerol compartment, particularly in Aerobic hearts. Conversely, counts in the aqueous soluble fraction and tissue fatty acid compartment dramatically declined with washout in both groups.
These latter two constituents correlated closely with the '4CO2 uptake pool in both groups ( Figure 7) production based on equilibrium labeling. PET studies also have recognized a late phase in the timeactivity curves, which has been attributed to tracer deposition in the endogenous lipid pool but which has been ignored as an element of metabolic activity. Analysis by PET would be even more compromised because of the short half-life of the "C-tracer and the difficulties in adequately labeling all intracellular lipid pools homogeneously within the allotted time constraints of the isotope. The following data were observed in this study. Metabolic analysis of the coronary effluent virtually precludes the existence of significant nonmetabolic routes of release of radioactivity in reflow after the moderate levels of ischemia imposed in these experiments. Although back diffusion cannot be categorically eliminated, the magnitude of this release, if present, must be trivial and would occur only during capillary transit. This should not obscure the rapid phase of the uptake curve. There was a modest HEART RATE (beats/min) FIGURE 6. Time constants of 14C02 release arrayed against heart rates in the two study groups (Aerobic hearts, open circles; IschemiclReflow hearts, closed circles). A significant inverse relation is noted, which is described for all animals by the expression Time Constant=57.1-0.25xheart rate.
decrease in the free fatty acid pool in Ischemic/ Reflow hearts. This reduction could represent either a decline in blood volume or an alteration in fatty acid uptake by the sarcolemma, perhaps as a residual consequence of the ischemic stress. The tissue fraction and pool sizes expressed as volume equivalents in our results are analogous to the distribution volume described by PET. Our studies revealed modest changes in these pool sizes. The pool size measured from 14CO2 efflux decreased, as did the tissue fraction composed of the aqueous soluble phase and free fatty acids. This same tissue fraction was rapidly lost during washout. These findings would not explain the prolonged clearance rates of the rapid exponential decay portion of the timeactivity curve described by PET in reflow. The PET data would imply a shift to a larger pool size, not a smaller one as found in these studies. The triacylglycerol tissue fraction in Ischemic/Reflow hearts did evince a trend toward larger values, but this pool manifests slow turnover kinetics and is thought to influence the late phase of time-activity curves.
These studies provide further evidence that the oxidation of fatty acid is not depressed during reperfusion. Although there is a trend toward decreased 14CO2 production after equilibrium in the Ischemic/ Reflow hearts, the significant decrease in '4CO2 and free fatty acid efflux expressed as a volume/flow equivalent is most likely an indication of the higher LAD flow in Aerobic hearts. This ratio represents the venous flow required to contain venous radioactivity if the venous concentration was equal to arterial concentration. As such, it is a function of perfusion. tions were noted during the ischemic interval, which continued to compromise oxygen consumption during reperfusion. Another possibility is that the two techniques, because they are interrogating cells with different metabolic activities (see above), are not measuring the same biological information from the heterogeneously perfused myocardium. The assumption of comparability of time constants might then be fallacious. A final concern deals with heart rate and its relation with the time constants of 14CO2 release. This relation was not dependent on oxygen consumption and suggested some nonmetabolic interaction that directly related to hemodynamic performance. Perhaps this determinant is influencing the two techniques differently, and the time-activity curves de- rived from PET should be reexamined with a focus on heart rate. In summary, the present data do not support a major metabolic alteration in fatty acid metabolism in reflow and are confirmatory of previous data acquired in this heart model.' Under the conditions of flow restriction in these studies, fatty acid oxidation was not significantly impaired in reperfusion but rather closely approximates metabolic behavior defined in aerobic hearts.
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